检索结果-南通市图书馆

Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第2期27卷 162-175页

作者： Kei Motooka Koichi Morishita Nami Ito Shinichiro Shinzaki Taku Tashiro Satoshi Nojima Kayoko Shimizu Mutsuhiro Date Natsumi Sakata Momoko Yamada shinji takamatsu Yoshihiro Kamada Hideki Iijima Tsunekazu Mizushima Eiichi Morii Tetsuo Takehara Eiji Miyoshi Department of Molecular Biochemistry and Clinical Investigation Osaka University Graduate School of MedicineSuita 565-0871OsakaJapan Department of Gastroenterology and Hepatology Osaka University Graduate School of MedicineSuita 565-0871OsakaJapan Department of Pathology Osaka University Graduate School of MedicineSuita 565-0871OsakaJapan FUJIFILM Wako Pure Chemical Corporation Amagasaki 661-0963HyogoJapan Department of Gastroenterological Surgery Osaka University Graduate School of MedicineSuita 565-0871OsakaJapan

BACKGROUND Inflammatory bowel disease(IBD)is a chronic,relapsing inflammation of the digestive *** fecal and serum biomarkers have been extremely important and supportive for monitoring of IBD,their low sensitivity and high variability characteristics limit clinical ***,the establishment of better biomarkers is *** is one of the most important glycosylation modifications of *** haptoglobin(Fuc-Hpt)is used as a biomarker for several cancers and inflammation-related *** recently established a novel glycan monoclonal antibody(mAb),designated 10-7G,which recognizes *** developed an enzyme-linked immunosorbent assay(ELISA)to measure serum levels of Fuc-Hpt(10-7G values).AIM To investigate the usefulness of the serum 10-7G values as a potential biomarker for monitoring disease activity in *** This was a case control *** tissues of IBD patients(n=10)were examined immunohistochemically using the 10-7G *** determined 10-7G values using serum from patients with ulcerative colitis(UC,n=110),Crohn’s disease(n=45),acute enteritis(AE,n=11),and healthy volunteers(HVs)who exhibited normal(n=20)or high(n=79)C-reactive protein(CRP)levels at medical *** investigated the correlation between the 10-7G value and various clinical parameters of IBD patients by correlation *** operating characteristic(ROC)curve analysis was performed to evaluate the usefulness of the 10-7G values as a biomarker for clinical and endoscopic remission of UC compared to conventional serum *** In the immunohistochemical analysis,positive 10-7G mAb staining was observed in lymphocytes infiltrating into inflammatory sites of the mucosal layer and lymphoid *** 10-7G values were significantly higher in patients with IBD(P<0.001)and AE(P<0.05)compared with *** addition,10-7G values were correlated with clinical examination parameters related to inflammation in patients with

关键词： Inflammatory bowel disease Biomarkers Glycosylation Fucosylated haptoglobin Prohaptoglobin Endoscopic remission

Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第17期22卷 4403-4410页

作者： Tomohiro Maekawa Yoshihiro Kamada Yusuke Ebisutani Makiko Ueda Tomoki Hata Koichi Kawamoto shinji takamatsu Kayo Mizutani Mayuka Shimomura Tomoaki Sobajima Hironobu Fujii Kotarosumitomo Nakayama Kimihiro Nishino Makoto Yamada Takashi Kumada Toshifumi Ito Hidetoshi Eguchi Hiroaki Nagano Eiji Miyoshi Department of Molecular Biochemistry and Clinical Investigation Osaka University Graduate School of Medicine Suita Osaka 565-0871 Japan Department of Surgery Osaka University Graduate School of Medicine Suita Suita Osaka 565-0871 Japan aMs New Otani Clinic Osaka Osaka 540-8570 Japan Department of Gastroenterology Ogaki Municipal Hospital Ogaki Gifu 503-8502 Japan Department of Gastroenterology and Hepatology Japan Community Health Care Organization Osaka Hospital Osaka Osaka 540-8570 Japan Department of Surgery Yamaguchi University Graduate School of Medicine Ube Yamaguchi 755-8505 Japan

AIM: To determine the efficacy of Mac-2 binding protein (Mac-2bp) for diagnosis of chronic ***: Fifty-nine healthy volunteers (HV), 162 patients with chronic pancreatitis (CP), and 94 patients with pancreatic ductal adenocarcinoma (PDAC) were enrolled in this study. We measured serum Mac-2bp using our developed enzyme-linked immunosorbent assay kit. Additional biochemical variables were measured using an automated analyzer (including aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, triglyceride, C-reactive protein, and amylase levels) or chemiluminescent enzyme immunoassay (carbohydrate antigen 19-9 and carcinoembryonic antigen). The ability of Mac-2bp to predict CP diagnosis accurately was assessed using receiver operating characteristic (ROC) ***: Serum Mac-2bp levels were significantly increased in CP patients compared to HV (P < 0.0001) and PDAC patients (P < 0.0001). Area under the ROC curve values of Mac-2bp for the discrimination of CP from HV and PDAC were 0.727 and 0.784, respectively. Multivariate analyses demonstrated that serum Mac-2bp levels were independent determinants for CP diagnosis from HV and PDAC patients. Immunohistological staining showed that Mac-2bp was expressed faintly in the pancreas tissues of both CP and PDAC patients. Serum aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, alkaline phosphatase, and triglyceride levels were significantly higher in patients with CP or PDAC. Serum Mac-2bp levels were highly correlated with protein levels of alanine aminotransferase, γ-glutamyltransferase, and C-reactive protein, but not amylase, suggesting that the damaged liver produces ***: Measurement of serum Mac-2bp may be a novel and useful biomarker for CP diagnosis as well as liver fibrosis in the general population.

关键词： Pancreatic ductal adenocarcinoma Chronic pancreatitis Biomarker Steatopancreatitis Mac-2 binding protein (LGALS3BP)

Protocol for laparoscopic cholecystectomy: Is it rocket science?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第47期22卷 10287-10303页

作者： Tomohide Hori Fumitaka Oike Hiroaki Furuyama Takafumi Machimoto Yoshio Kadokawa Toshiyuki Hata Shigeru Kato Daiki Yasukawa Yuki Aisu Maho Sasaki Yusuke Kimura Yuichiro takamatsu Masato Naito Masaya Nakauchi Takahiro Tanaka Daigo Gunji Kiyokuni Nakamura Kiyoko Sato Masahiro Mizuno Taku Iida Shintaro Yagi shinji Uemoto Tsunehiro Yoshimura Department of Gastrointestinal and General Surgery Tenriyorodusoudanjyo Hospital Department of Gastrointestinal Surgery Mitsubishi Kyoto Hospital Department of Anesthesiology Mitsubishi Kyoto Hospital Department of Gastroenterology and Hepatology Mitsubishi Kyoto Hospital Department of Hepatobiliary Pancreatic Surgery Kyoto University Hospital

Laparoscopic cholecystectomy(LC) does not require advanced techniques, and its performance has therefore rapidly spread worldwide. However, the rate of biliary injuries has not decreased. The concept of the critical view of safety(CVS) was first documented two decades ago. Unexpected injuries are principally due to misidentification of human factors. The surgeon's assumption is a major cause of misidentification, and a high level of experience alone is not sufficient for successful LC. We herein describe tips and pitfalls of LC in detail and discuss various technical ***, based on a review of important papers and our own experience, we summarize the following mandatory protocol for safe LC:(1) consideration that a high level of experience alone is not enough;(2) recognition of the plateau involving the common hepatic duct and hepatic hilum;(3) blunt dissection until CVS exposure;(4) Calot's triangle clearance in the overhead view;(5) Calot's triangle clearance in the view from underneath;(6) dissection of the posterior right side of Calot's triangle;(7) removal of the gallbladder body; and(8) positive CVS exposure. We believe that adherence to this protocol will ensure successful and beneficial LC worldwide, even in patients with inflammatory changes and rare anatomies.

关键词： Laparoscopic cholecystectomy Gallbladder Critical view of safety biliary injury Protocol

A Phase II Trial of Preoperative Chemoradiotherapy with Oral DPD-Inhibitory Fluoropyrimidines in Patients with Advanced Rectal Cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2012年第6期3卷 989-995页

作者： Masanori Hotchi Hiroshi Okitsu Murato Miura Madoka Hamada Yasuhide Sonaka Yoh Fukuda Tsutomu Ando shinji Kuratate Department of Surgery Kochi Health Sciences Center Kochi Japan Department of Surgery National Hospital Organization Kochi National Hospital Kochi Japan Department of Surgery Shikoku Central Hospital Ehime Japan Department of Surgery Takamatsu City Hospital Takamatsu Japan Department of Surgery Tokushima Municipal Hospital Tokushima Japan Department of Surgery Tokushima Prefectural Central Hospital Tokushima Japan Department of Surgery Tokushima Red Cross Hospital Tokushima Japan Department of Surgery Tokushima University Hospital Tokushima Japan

Background: Preoperative chemoradiotherapy (CRT) with 5-FU has been widely used to improve local control of disease and to preserve anal sphincter in the treatment of rectal cancer. UFT and S-1 as oral dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidines enhance the therapeutic effect of 5-FU by modulating its metabolic pathways. The purpose of this study was to evaluate the efficacy and toxicity of CRT using UFT versus S-1 in patients with locally advanced rectal cancer. Methods: Fifty-nine patients who received preoperative CRT (40 Gy radiotherapy) were randomly assigned to either UFT or S-1 groups. UFT and S-1 were administered during the radiotherapy course. Response to CRT was determined using a histopathologic examination and RECIST of surgically resected specimens and classified as responders (CR, PR and grade 2, 3) or nonresponders (SD, PD and grade 0, 1). Results: All patients were randomly allocated to S-1 group (n = 30) or UFT group (n = 29). Pathological response rate (Grade2 and Grade3) was 57% in the S-1 group and 45% in the UFT group (p = 0.36). Pathological complete response (CR) rate (Grade3) was 7% in the S-1 group and 4% in the UFT group (p = 0.98). There was no statistically significant difference between the two groups in regard to the response rate of RECIST (p = 0.52). There was no statistically significant difference between the groups based on the downstaging rate, resection of tumor, sphincter preservation and marginal invasion. The incidence of Grade 3 diarrhea was significantly more frequent in the S-1 group (7%) compared with the UFT group (0%) (p = 0.02). Conclusion: The results supported the conclusion that CRT using UFT or S-1 is effective and feasible for patients with locally advanced rectal cancer.

关键词： S-1 UFT Chemoradiation Rectal Cancer